DelveInsight's latest report reveals 8+ companies developing 10+ therapies for hypersomnia, with Avadel's Lumryz, Zevra's KP1077, and Alkermes' ALKS 2680 among the key candidates advancing through clinical trials.
NeuroTherapia's NTRX-07, an oral neuroinflammatory inhibitor, receives EMA approval for a Phase 2 trial in Alzheimer's disease, aiming to improve neuronal function.
Axsome Therapeutics' AXS-12 (reboxetine) significantly reduced cataplexy attacks compared to placebo in the Phase 3 ENCORE trial, meeting its primary endpoint.